POST-COVID-19 LESIONS OF THE MUSCULOSKELETAL SYSTEM IN ADOLESCENTS: APPROACHES TO PHARMACOTHERAPY

DOI: https://doi.org/10.29296/25877305-2022-08-02
Issue: 
8
Year: 
2022

L. Evert(1, 2), MD; T. Potupchik(3), Сandidate of Medical Sciences; Yu. Kostyuchenko(1); O. Chudinova(2), Сandidate of Biological Sciences; E. Panicheva(3), Сandidate
of Medical Sciences
1-Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch
of the Russian Academy of Sciences», Research Institute of Medical Problems
of the North
2-N.F. Katanov Khakass State University, Ministry of Science and Higher Education of the Russia, Abakan
3-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry
of Health of the Russia

A review of information on the most common violations of various organs and systems in adults and children who have had a coronavirus infection has been conducted. Etiopathogenetic aspects and the main clinical manifestations of post-COVID-19 syndrome (PCS) in people of different ages are highlighted. The results of our own study are included, which showed a high incidence of disorders of the musculoskeletal and other body systems in COVID-19 convalescents. Various strategies for the treatment of bridge-like disorders are highlighted. As a pharmacological correction, the possibility of therapy using of nonsteroidal anti-inflammatory drugs; central muscle relaxants; coanalgesics: anticonvulsants and antidepressants; vitamin and mineral complexes; osteoprotectors is being considered. Therapy and prevention of PCS should include correction of functional disorders, pain control, consistent physical, psychological and social rehabilitation.
Keywords: 
adolescents
musculoskeletal system
post-COVID-19 syndrome
vessels
muscles
pharmacotherapy

References: 
  1. Amelin A.V., Tarasova S.V., Ignatov Yu.D. et al. Antidepressants with different action mechanisms in the treatment of chronic daily headache. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2007; 9: 38–44 (in Russ.).
  2. Bochanova E.N., Gatskikh I.V., Potupchik T.V. et al. Comparative analysis of multivitamins for children. Problems of biological, medical and pharmaceutical chemistry. 2020; 23 (11): 10–5 (in Russ.). DOI: 10.29296/25877313-2020-11-02
  3. Buryachkovskaya L.I., Melkumyants A.M., Lomakin N.V., Antonova O.A., Ermiskin V.V. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021; 23 (6): 469–76 (in Russ.). DOI: 10.26442/20751753.2021.6.200939
  4. Voznesenskaya T.G. Chronic pain and depression. Pharmateca. 2008; 6 (160): 105 (in Russ.).
  5. Godzenko A.A., Badokin V.V. Local therapy of myofascial pain syndrome. RMJ. Rheumatology. 2007; 26: 1998–2003 (in Russ.).
  6. Golovanova V.A., Parfenov V.A. Treatment of musculoskeletal pain during covid-19 pandemics. Clinical pharmacology and therapy. 2022; 31 (1): 24–31 (in Russ.). DOI: 10.32756/0869-5490-2022-1-24-31
  7. State Register of medicinal products [Electronic resource]. Access mode: https://grls.rosminzdrav.ru/ (in Russ.).
  8. Danilov A.B. Pain therapy. Diagnosis and treatment of fibromyalgia. Effective pharmacotherapy. Neurology. 2010; 5: 6–12 (in Russ.).
  9. Dedov D. New coronavirus infection: clinical and pathogenetic aspects, prevention, importance of vitamins and trace elements. Vrach. 2022; 33 (2): 47–9. DOI: 10.29296/25877305-2022-02-07
  10. Dedov D.V., Marchenko S.D. Vitamins, iron, zinc, selenium, selenium-containing drugs in the complex prevention of complications and treatment of patients with COVID-19. Pharmacy. 2022; 71 (1): 5–9. DOI 10.29296/25419218-2022-01-01
  11. Ekusheva E.V. Lamotrigine in treatment of chronic pain syndromes. Medical alphabet. 2020; 22: 5–8 (in Russ.). DOI: 10.33667/2078-5631-2020-22-5-8
  12. Yershov V.E., Krivova A.V., Zakharov V.P. et al. Experience of using a systemic glucocorticosteroid as an initial therapy for post-COVID-19 arthritis in outpatient practice. Russian Medical Inquiry. 2021; 5 (5): 252–6 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-252-256
  13. Igisheva L.N. Nonsteroidal anti-inflammatory drugs in the clinical practice of a pediatrician. Mother and child in Kuzbass. 2006; 3 (26): 9–13 (in Russ.).
  14. Karateev A.E. Simple analgesic paracetamol. RMJ. 2010; 9: 581 (in Russ.).
  15. Karateev A.E., Amirdzhanova V.N., Nasonov E.L. et al. “Post-COVID syndrome”: The focus is on musculoskeletal pain. Rheumatology Science and Practice. 2021; 59 (3): 255–62 (in Russ.). DOI: 10.47360/1995-4484-2021-255-262
  16. The best vitamins for teenagers [Electronic resource]. Access mode: https://www.rigla.ru/about/news/2020/vitaminy-podrostkam (in Russ.).
  17. Mikhno L., Levshin I., Polikarpochkin A. et al. Use of pharmacological agents to preserve, restore, and improve the performance of young hockey players. Vrach. 2018; 29 (9): 67–71. (in Russ.). DOI: 10.29296/25877305-2018-09-16
  18. Nasonov E.L. Coronavirus disease 2019 (covid-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020; 58 (2): 123–32 (in Russ.). DOI: 10.14412/1995-4484-2020-123-132
  19. Ovsyannikova E.M., Korovina N.A. Questions of optimal choice of NSAIDs in pediatric practice. Meditsinskiy sovet = Medical Council. 2014; 6: 35–9 (in Russ.). DOI: 10.21518/2079-701X-2014-6-35-39
  20. Orthomol tendo – tendon health at any age [Electronic resource]. Access mode: https://www.lsgeotar.ru/ortomol-tendo-18195.html (in Russ.).
  21. Parfenov V.A. Low back pain: causes, diagnosis, and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2009; 1 (1): 19–22 (in Russ.). DOI: 10.14412/2074-2711-2009-17
  22. Savustyanenko A.V. Carbamazepine use for neuropathic pain treatment: review of studies. International Neurological Journal. 2011; 2 (40):107–15 (in Russ.).
  23. Candan S.A., Elibol N., Abdullahi A. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19. Physiother Theory Pract. 2020; 36 (6): 663–8. DOI: 10.1080/09593985.2020.1766181
  24. Capaccione K.M., Yang H., West E. et al. Pathophysiology and imaging findings of COVID-19 infection: An organ-system based review. Acad Radiol. 2021; 28 (5): 595–607. DOI: 10.1016/j.acra.2021.01.022
  25. Carfi A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–5. DOI: 10.1001/jama.2020.12603
  26. Darif D., Hammi I., Kihel A. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. 2021; 18 (153): 104799. DOI: 10.1016/j.micpath.2021.104799
  27. De Giorgio M.R., Di Noia S., Morciano C. et al. The impact of SARS-CoV-2 on skeletal muscles. Acta Myol. 2020; 39 (4): 307–12. DOI: 10.36185/2532-1900-034
  28. Demeco A., Marotta N., Barletta M. et al. Rehabilitation of patients post-COVID-19 infection: A literature review. J Int Med Res. 2020; 48 (8): 300060520948382. DOI: 10.1177/0300060520948382
  29. Dworkin R.H., O’Connor A.B., Audette J. Recommendation for the pharmacological management of neuropathic pain: an overwiew and literature update. Mayo Clin Proc. 2010; 85 (3): 3–14. DOI: 10.4065/mcp.2009.0649
  30. Dworkin R.H., О’Connor A.B., Backonja M. Pharmacologic management of neuropathic pain: evidence-based recommen dations. Pain. 2007; 132 (23): 7–51. DOI: 10.1016/j.pain.2007.08.033
  31. Galal I., Mohamed Hussein A., Amin M. et al. Determinants of persistent post-COVID-19 symptoms: Value of a novel COVID-19 symptom score. Egypt J Bronchol. 2021; 15: 10. DOI: 10.1186/s43168-020-00049-4
  32. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): 1211–859. DOI: 10.1016/S0140-6736(17)32154-2
  33. Himmels J.P.W., Qureshi S.A., Brurberg K.G. et al. COVID-19: Long-term effects of COVID-19. Rapid review. URL: https://www.fhi.no/en/publ/2021/Long-Term-Effects-of-COVID-19
  34. Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Res Sq. 2021: rs.3.rs-266574. DOI: 10.21203/rs.3.rs-266574/v1
  35. Marinangeli F., Giarratano A., Petrini F. Chronic pain and COVID-19: Pathophysiological, clinical and organizational issues. Minerva Anestesiol. 2021; 87 (7): 828–32. DOI: 10.23736/S0375-9393.20.15029-6
  36. Nalbandian A., Sehgal K., Gupta A. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15. DOI: 10.1038/s41591-021-01283-z
  37. Oronsky B., Larson C., Hammond T.C. et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021; 20: 1–9. DOI: 10.1007/s12016-021-08848-3
  38. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021; 9 (3): e14726. DOI: 10.14814/phy2.14726
  39. Weng L.M., Su X., Wang X.Q. Pain symptoms in patients with coronavirus disease (COVID-19): A literature review. J Pain Res. 2021; 14: 147–59. DOI: 10.2147/JPR.S269206
  40. Wong A.Y., MacKenna B., Morton C.E. et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021; 80 (7): 943–51. DOI: 10.1136/annrheumdis-2020-219517
  41. Yang R., Dunn J.F., Su D. et al. Lamotrigine inhibits TRESK regulated by G protein coupled receptor agonist. J Neurosci. 2018; 367: 368–75. DOI: 10.1016/j.bbrc.2008.01.008
  42. Yang Y.C., Chou C.L., Kao C.L. Exercise, nutrition, and medication considerations in the light of the COVID pandemic, with specific focus on geriatric population: A literature review. J Chin Med Assoc. 2020; 83 (11): 977–80. DOI: 10.1097/JCMA.0000000000000393